Zymeworks Sees Current Cash Resources, Expected Payments to Support Operations Into H2 2027

MT Newswires Live06:04

Zymeworks (ZYME) said Wednesday it exited 2024 with around $324 million in cash that should support its operations at projected levels into H2 2027, when combined with anticipated milestone payments.

The $324 million cash, cash equivalent reserve on Dec. 31 does not include a $25 milestone payment due in the current quarter from Jazz Pharmaceuticals (JAZZ) that was triggered by approval in the US of Ziihera bispecific antibody treatment for HER2-positive biliary tract cancer.

Zymeworks also said the company is well-positioned for additional progress with its drug pipeline to potential treat various autoimmune and inflammatory diseases as well as hematological cancers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2502089383?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 06:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502089383","market":"us","top_or_hot":-1,"title":"Zymeworks Sees Current Cash Resources, Expected Payments to Support Operations Into H2 2027","media":"MT Newswires Live","content":"<html><body><p> Zymeworks (ZYME) said Wednesday it exited 2024 with around $324 million in cash that should support its operations at projected levels into H2 2027, when combined with anticipated milestone payments.</p><p>The $324 million cash, cash equivalent reserve on Dec. 31 does not include a $25 milestone payment due in the current quarter from Jazz Pharmaceuticals (JAZZ) that was triggered by approval in the US of Ziihera bispecific antibody treatment for HER2-positive biliary tract cancer.</p><p>Zymeworks also said the company is well-positioned for additional progress with its drug pipeline to potential treat various autoimmune and inflammatory diseases as well as hematological cancers.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zymeworks Sees Current Cash Resources, Expected Payments to Support Operations Into H2 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZymeworks Sees Current Cash Resources, Expected Payments to Support Operations Into H2 2027\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-09 06:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zymeworks (ZYME) said Wednesday it exited 2024 with around $324 million in cash that should support its operations at projected levels into H2 2027, when combined with anticipated milestone payments....</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2502089383","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502089383","pubTimestamp":1736373896,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zymeworks  said Wednesday it exited 2024 with around $324 million in cash that should support its operations at projected levels into H2 2027, when combined with anticipated milestone payments.The $324 million cash, cash equivalent reserve on Dec. 31 does not include a $25 milestone payment due in the current quarter from Jazz Pharmaceuticals  that was triggered by approval in the US of Ziihera bispecific antibody treatment for HER2-positive biliary tract cancer.Zymeworks also said the company is well-positioned for additional progress with its drug pipeline to potential treat various autoimmune and inflammatory diseases as well as hematological cancers.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ZYME":"ZYMEWORKS INC (US)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","JAZZ":"爵士制药","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓"},"translate_title":"Zymeworks预计当前现金资源和预期付款将支持2027年下半年的运营","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1,"ZYME":0.9},"content_text":"Zymeworks (ZYME) said Wednesday it exited 2024 with around $324 million in cash that should support its operations at projected levels into H2 2027, when combined with anticipated milestone payments.The $324 million cash, cash equivalent reserve on Dec. 31 does not include a $25 milestone payment due in the current quarter from Jazz Pharmaceuticals (JAZZ) that was triggered by approval in the US of Ziihera bispecific antibody treatment for HER2-positive biliary tract cancer.Zymeworks also said the company is well-positioned for additional progress with its drug pipeline to potential treat various autoimmune and inflammatory diseases as well as hematological cancers.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502089383"}